Financials data is unavailable for this security.
View more
Year on year Ningbo Menovo Pharmaceutical Co Ltd 's revenues fell -16.51% from 1.46bn to 1.22bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 338.86m to 11.59m, a -96.58% decrease.
| Gross margin | 29.16% |
|---|---|
| Net profit margin | 0.24% |
| Operating margin | 1.15% |
| Return on assets | 0.07% |
|---|---|
| Return on equity | -0.02% |
| Return on investment | 0.10% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Ningbo Menovo Pharmaceutical Co Ltd fell by 263.06m. Cash Flow from Financing totalled 54.87m or 4.51% of revenues. In addition the company generated 9.13m in cash from operations while cash used for investing totalled 323.61m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.67 |
|---|---|
| Tangible book value per share | 8.71 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.24 |
|---|---|
| Quick ratio | 0.78 |
| Total debt/total equity | 0.748 |
|---|---|
| Total debt/total capital | 0.4176 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -87.88% and -96.64%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 0.32% |
|---|---|
| Div growth rate (5 year) | -32.54% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -36.18 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -104.01 |
More ▼
